About Immuneel
Immuneel is a company based in Bengaluru (India) founded in 2018 by Siddhartha Mukherjee and Kiran Mazumdar Shaw. It operates as a HealthTech. Immuneel has raised $39.34 million across 4 funding rounds from investors including Kotak Mahindra Bank, Apollo Hospitals and Syngene. The company has 96 employees as of April 06, 2024. Immuneel offers products and services including CAR-T Cell Therapy. Immuneel operates in a competitive market with competitors including Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.
- Headquarter Bengaluru, India
- Employees 96 as on 06 Apr, 2024
- Founders Siddhartha Mukherjee, Kiran Mazumdar Shaw
- Stage Minicorn
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Immuneel Therapeutics Private Limited
- Date of Incorporation 20 Dec, 2018
- Jurisdiction Bengaluru, Karnataka, India
-
Annual Revenue
$514.04 K (USD)441.27as on Mar 31, 2023
-
Net Profit
-$4.71 M (USD)-26.81as on Mar 31, 2023
-
EBITDA
-$4.7 M (USD)-38.04as on Mar 31, 2023
-
Total Equity Funding
$39.34 M (USD)
in 4 rounds
-
Latest Funding Round
$11.98 M (USD), Series A
Jun 24, 2024
-
Investors
Kotak Mahindra Bank
& 18 more
-
Employee Count
96
as on Apr 06, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Immuneel
Immuneel offers a comprehensive portfolio of products and services, including CAR-T Cell Therapy.
Genetically modified immune cells are used to fight cancer.
People of Immuneel
Unlock access to complete
Funding Insights of Immuneel
Immuneel has successfully raised a total of $39.34M across 4 strategic funding rounds. The most recent funding activity was a Series A round of $11.98 million completed in June 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Immuneel
Immuneel has secured backing from 19 investors, including institutional, venture fund, and angel investors. Prominent investors backing the company include Kotak Mahindra Bank, Apollo Hospitals and Syngene.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital investment and global platform support for startups.
|
Locked | Locked | Locked | |
|
Early stage VC firm investing in the US
|
Locked | Locked | Locked | |
|
Investments in life sciences, technology, healthtech, and crypto sectors from global locations.
|
Locked | Locked | Locked |
Investor details for Immuneel
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Immuneel
Investment portfolio details for Immuneel
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Immuneel
Detailed financials for Immuneel
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Immuneel Comparisons
Peer comparison for Immuneel
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Immuneel
Immuneel operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed.
|
|
| Locked | Locked | Locked |
Small molecules are developed for cancer and skin disease treatments.
|
|
| Locked | Locked | Locked |
Cancer therapies are developed using selective pathway inhibitors.
|
Detailed competitors of Immuneel
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Immuneel
Complete news archive for Immuneel
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Immuneel
Immuneel was founded in 2018 and raised its 1st funding round 1 year after it was founded.
Immuneel is headquartered in Bengaluru, India. It is registered at Bengaluru, Karnataka, India.
Immuneel is a funded company, having raised a total of $39.34M across 4 funding rounds to date.
As of Apr 06, 2024, the latest employee count at Immuneel is 96.
Annual revenue of Immuneel is $514.04K as on Mar 31, 2023.
Immuneel Therapeutics is dedicated to making breakthrough cancer treatments, such as cell and gene therapies including CAR-T cell therapy, accessible and affordable in India. The company operates within the healthcare and biotechnology sector, addressing the critical gap in access to next-generation cancer care. Efforts are made to serve Indias growing cancer burden while contributing to the global landscape of innovative therapies. Collaboration with global partners is emphasized to develop and deliver high-quality treatments. The mission is to improve patient outcomes and expand access to advanced medical solutions across the region and beyond.
Immuneel's top competitors include Moderna, Jazz Pharmaceuticals and Advanced Accelerator Applications.
Immuneel offers CAR-T Cell Therapy.
Immuneel has 19 investors. Key investors include Kotak Mahindra Bank, Apollo Hospitals, Syngene, Khosla Ventures, and Eight Roads Ventures.
The valuation of Immuneel is $70.46M as of Jun 2024.